Sab biotherapeutics provides sab-142 trial update

Miami beach, fla., april 16, 2024 (globe newswire) -- sab biotherapeutics, inc. (nasdaq:  sabs ), (“sab” or the “company”), a clinical-stage biopharmaceutical company with a novel immunotherapy platform that is developing human anti-thymocyte immunoglobulin (higg) for delaying the onset or progression of type 1 diabetes (t1d), today announced their chief medical officer, dr. alexandra kropotova, md, mba disclosed that sab has completed dosing the third cohort for sab-142 with no observation of serum sickness thus far.
SABS Ratings Summary
SABS Quant Ranking